BRISTOL MYERS SQUIBB
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- -
- Established
- 1989-01-01
- Employees
- 30K
- Market Cap
- $97.5B
- Website
- https://www.bms.com/
A Treatment IND (Investigational New Drug) Protocol for the Use of Videx (2',3'-Dideoxyinosine, ddI) in Patients With Acquired Immunodeficiency Syndrome (AIDS) or AIDS- Related Complex (ARC) Who Are Intolerant to Zidovudine (Retrovir)
Not Applicable
Completed
- Conditions
- HIV Infections
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2007-08-16
- Lead Sponsor
- Bristol-Myers Squibb
- Registration Number
- NCT00002028
- Locations
- 🇺🇸
Bristol - Myers Squibb Co, Princeton, New Jersey, United States
Safety and Effectiveness of a New Protease Inhibitor, BMS-232632, in HIV-Positive Patients Who Have Received Previous Treatment
Phase 2
Completed
- Conditions
- HIV Infections
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2011-05-04
- Lead Sponsor
- Bristol-Myers Squibb
- Registration Number
- NCT00004584
- Locations
- 🇺🇸
HIV Clinical Research, Fort Lauderdale, Florida, United States
🇺🇸Infectious Disease Specialists of Atlanta, Decatur, Georgia, United States
🇺🇸Albany Med College, Albany, New York, United States
© Copyright 2025. All Rights Reserved by MedPath